Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinding Evaluation of ZFXN Oral Liquid
NCT05483595Completed
- Sponsor
- Guangzhou University of Chinese Medicine
- Start
- Sep 2022
- Primary completion
- Jun 2023
- Countries
- 1
01
Overview
Randomised, double-blind trial in intracerebral hemorrhage (ICH) comparing ZFXN group with Placebo group (2 arms). Primary endpoint: Percentage of ZFXN response at 10 minutes. Started Sep 2022; status: completed.
02
Drugs
Zhongfengxingnao formula
03
Conditions
intracerebral hemorrhage (ICH)
Beyond the preview
Go deeper on NCT05483595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05483595.